Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.
Journal of internal medicine
Severely ill COVID-19 patients have a high risk of admission to the intensive-care unit (ICU) and requirement for mechanical ventilation (MV), with in-hospital mortality reported as 18-79% globally.1-4 . Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is FDA approved for the management of CAR T-cell related Cytokine Release Syndrome (CRS) and may have utility in treatment of some COVID-19 patients. We describe the clinical characteristics and initial outcomes of a cohort of patients treated with tocilizumab at the Swedish Medical Center in Seattle, Washington.
Patel, Krish; Gooley, Ted A; Bailey, Neil; Bailey, Megumi; Hegerova, Livia; Batchelder, Ami; Holdread, Heather; Dunleavy, Vanessa; Downey, Tyler; Frisvold, Jens; Megrath, Samantha; Pagarigan, Krystle; Szeto, Jennie; Rueda, Justin; Islam, Adel; Maree, Cynthia L; Nyatsatsang, Sonam; Bork, Sarah E; Lipke, Anne B; O'Mahony, D Shane; Wagner, Teresa E; Pulido, Juan; Mignone, John; Youssef, Samuel; Hartman, Matthew; Goldman, Jason D; and Pagel, John M, "Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients." (2020). Articles, Abstracts, and Reports. 3319.